Medico Remedies Ltd (BSE: 540937) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹157 Cr, it ranks #2,850 by market cap among the 6,197 Indian listed companies on FinBizNet, and #41 of 63 in Pharmaceuticals. At ₹18.49 (as of 16 Nov 2026), the share price is 65.9% below its 52-week high of ₹54.24 and 3.8% above its 52-week low of ₹17.81. The share price is down 63.0% over one year and down 61.5% over three months.
| Current Price | ₹18.49 |
|---|---|
| Market Cap | ₹157 Cr |
| BSE Code | 540937 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 12 |
| Return on Equity | 19.05% |
| Return on Assets | 6.38% |
| 52-Week Range | ₹17.81 – ₹54.24 |
| 1-Year Price Change | -63.0% |
| 3-Month Price Change | -61.5% |
| Beta (1Y) | 0.76 |
| Headquarters | Mumbai, Maharashtra |
| Website | medicoremedies.com |
| Revenue | ₹74 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 3.2% |
| EPS (Basic) | ₹0.29 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Medico Remedies Ltd reported revenue of ₹74 Cr in Q2 FY27, up 40.5% from ₹53 Cr in Q2 FY26 and up 6.6% from ₹69 Cr in Q1 FY27. It posted a net profit of ₹2 Cr for the quarter, against a net profit of ₹3 Cr in Q2 FY26 (down 7.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹38 Cr (Q1 FY26) to ₹74 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹74 Cr | ₹2 Cr | 3.2% |
| Q1 FY27 | ₹69 Cr | ₹3 Cr | 3.6% |
| Q4 FY26 | ₹57 Cr | ₹6 Cr | 10.3% |
| Q3 FY26 | ₹59 Cr | ₹3 Cr | 4.9% |
| Q2 FY26 | ₹53 Cr | ₹3 Cr | 4.9% |
| Q1 FY26 | ₹38 Cr | ₹2 Cr | 4.8% |
| Q4 FY25 | ₹41 Cr | ₹4 Cr | 10.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 61.38% of Medico Remedies Ltd's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 70.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
1. Pharmaceuticals-This segment manufactures and sells pharmaceutical preparations.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Medico Remedies Ltd | ₹157 Cr | 12 | 19.05% | ₹74 Cr | -63.0% |
Listed by market capitalisation. Ratios are shown for context only.
Medico Remedies Ltd is trading at ₹18.49, with a market capitalisation of ₹157 Cr.
Medico Remedies Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Medico Remedies Ltd has a P/E of 12 and a return on equity of 19.05%.
Medico Remedies Ltd is listed on the BSE under the scrip code 540937.
Medico Remedies Ltd's share price is down 63.0% over one year and down 61.5% over three months. Its 52-week range is ₹17.81 to ₹54.24.
In Q2 FY27, Medico Remedies Ltd reported revenue of ₹74 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.29 (standalone, parsed from the company's exchange filing).
Medico Remedies Ltd reported revenue of ₹74 Cr in Q2 FY27, up 40.5% from ₹53 Cr in Q2 FY26 and up 6.6% from ₹69 Cr in Q1 FY27.
Promoters held 61.38% of Medico Remedies Ltd's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.